Abstract:The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.

Liver fibrosis and extracellular matrix

Extracellular Matrix and Liver Disease

Liver Fibrosis and Altered Matrix Synthesis

Genesis of hepatic fibrosis and its biochemical markers

Liver fibrosis and inflammation. A review

Extracellular Matrix Metabolism and Fibrotic Disease

Liver extracellular matrix in health and disease

Monitoring Fibrogenic Progression in the Liver.

Collagen biology and non‐invasive biomarkers of liver fibrosis

Extracellular Matrix Remodeling in Chronic Liver Disease

Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues

Pathophysiology of Liver Fibrosis

Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution

Novel insights into the function and dynamics of extracellular matrix in liver fibrosis

Advances in Serum Diagnosis of Liver Fibrosis

Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis

Determination of Serum Fibrosis Indexes in Patients with Chronic Hepatitis and Its Significance

Hepatic fibrosis: From bench to bedside

Liver fibrosis: Pathophysiology and clinical implications

The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells